Carmustine (BCNU) in Silicone Oil Prevents Proliferation of Cultured Cells

  • Felipe I. Tolentino
  • Victorio N. Cajita
  • Hum Chung
  • Norio Ueno
  • Miguel F. Refojo


In proliferative vitreoretinopathy (PVR), unwanted cellular growth may occur under or over the retina following retinal detachment surgery or penetrating injury to the eye, and this often leads to unsuccessful surgery.1 Meticulous membrane removal with the adjunctive use of silicone oil for prolonged tamponade has increased surgical success rates2,3; however, PVR may recur despite this surgical modality.4


Balance Salt Solution Predetermined Time Interval Vitreous Cavity Proliferative Vitreoretinopathy Retinal Detachment Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ryan SJ. The pathophysiology of proliferative vitreo-retinopathy in its management. Am J Ophthalmol 1985; 100:188–193.PubMedGoogle Scholar
  2. 2.
    Grey HB, Leaver PK. Silicone oil in the treatment of massive preretinal retraction. I. Results in 105 eyes. Br J Ophthalmol 1979; 63:355–360.PubMedCrossRefGoogle Scholar
  3. 3.
    Gonvers M. Temporary silicone oil tamponade in the management of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 1985; 100:239–245.PubMedGoogle Scholar
  4. 4.
    Glaser BM. Treatment of giant retinal tears combined with proliferative vitreoretinopathy. Ophthalmology 1986;93:1193–1197.PubMedGoogle Scholar
  5. 5.
    Litin BS, Jones MA, Kwong EM, Herschier J. Effect of antineoplastic drugs on cell proliferation-individually and in combination. Ophthalmic Surg 1985; 16:34–39.PubMedGoogle Scholar
  6. 6.
    Fiscella R, Elvart J, Peyman GA, Yue B. In vitro evaluation of cellular inhibitory potential of various antineoplastic drugs and dexamethasone. Ophthalmic Surg 1985; 16:247–249.PubMedGoogle Scholar
  7. 7.
    Blumenkrantz MS, Harter MK, Hajek AS. Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol 1987; 105:396–399.Google Scholar
  8. 8.
    Stern WH, Lewis GP, Erickson PA, et al. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol 1983; 96:33–42.PubMedGoogle Scholar
  9. 9.
    DeVita VT, Denham C, Davidson JD, Oliverio VT. The physiological disposition of the carcinostatic l,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) in man and animals. Clin Pharm Ther 1967; 8:566–577.Google Scholar
  10. 10.
    Loo TL, Dion RL. Colorimetric method for the determination of l,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci 1965; 54:809–810.PubMedCrossRefGoogle Scholar
  11. 11.
    Tresher RJ, Ehrenberg M, Machemer R. Gasmediated gas compression: an experimental alternative to mechanized vitrectomy. Graefes Arch Clin Exp Ophthalmol 1984; 221:192–198.CrossRefGoogle Scholar
  12. 12.
    Lambrou FH, Burke JM, Arberg TM. Silicone oil enhances proliferation in experimental proliferative vitreo-retinopathy. Invest Ophthalmol Vis Sci 1987; 28(Suppl):290.Google Scholar
  13. 13.
    Miller DF, Bay JW, Lederman RJ, et al. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985; 92:402–406.PubMedGoogle Scholar
  14. 14.
    Liu HS, Perry HD, Refojo MF. Tolerance of normal rabbit eyes to the antineoplastic carmustine. Ophthalmologica 1980; 181:41–46.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1988

Authors and Affiliations

  • Felipe I. Tolentino
  • Victorio N. Cajita
  • Hum Chung
  • Norio Ueno
  • Miguel F. Refojo

There are no affiliations available

Personalised recommendations